These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23341703)

  • 1. Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia.
    Toshikuni N; Fukumura A; Hayashi N; Nomura T; Tsuchishima M; Arisawa T; Tsutsumi M
    J Clin Biochem Nutr; 2013 Jan; 52(1):82-8. PubMed ID: 23341703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis.
    Toshikuni N; Tsuchishima M; Fukumura A; Arisawa T; Tsutsumi M
    Gastroenterol Res Pract; 2017; 2017():9127847. PubMed ID: 28912806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population.
    Yang S; Kwak S; Lee JH; Kang S; Lee SP
    PLoS One; 2019; 14(11):e0224626. PubMed ID: 31682638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiological investigation of fatty liver disease in Northwest China].
    Yan H; Lu X; Gao Y; Luo J
    Zhonghua Gan Zang Bing Za Zhi; 2015 Aug; 23(8):622-7. PubMed ID: 26447628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epidemiological survey of prevalence of fatty liver and its risk factors in a general adult population of Shanghai].
    Fang JG; Zhu J; Li XJ; Li R; Dai F; Song XM; Chen L; Li F; Chen SY
    Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):83-8. PubMed ID: 15727689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease.
    Kim D; Kim W; Joo SK; Kim JH; Harrison SA; Younossi ZM; Ahmed A
    Liver Int; 2019 Feb; 39(2):332-341. PubMed ID: 30298568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery.
    Xanthakos SA; Jenkins TM; Kleiner DE; Boyce TW; Mourya R; Karns R; Brandt ML; Harmon CM; Helmrath MA; Michalsky MP; Courcoulas AP; Zeller MH; Inge TH;
    Gastroenterology; 2015 Sep; 149(3):623-34.e8. PubMed ID: 26026390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Arase Y; Shiraishi K; Anzai K; Sato H; Teramura E; Tsuruya K; Hirose S; Deguchi R; Toyoda M; Mine T; Kagawa T
    Clin Drug Investig; 2019 Jul; 39(7):631-641. PubMed ID: 30993553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Moh Moh MA; Jung CH; Lee B; Choi D; Kim BY; Kim CH; Kang SK; Mok JO
    Diab Vasc Dis Res; 2019 Mar; 16(2):186-195. PubMed ID: 30428692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis].
    Choi SY; Kim D; Kang JH; Park MJ; Kim YS; Lim SH; Kim CH; Lee HS
    Korean J Hepatol; 2008 Mar; 14(1):77-88. PubMed ID: 18367860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.
    Sonmez A; Nikolic D; Dogru T; Ercin CN; Genc H; Cesur M; Tapan S; Karslioğlu Y; Montalto G; Banach M; Toth PP; Bagci S; Rizzo M
    J Clin Lipidol; 2015; 9(4):576-82. PubMed ID: 26228676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
    Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
    Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
    Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Diabetes Mellitus and Insulin on Nonalcoholic Fatty Liver Disease in the Morbidly Obese.
    Strey CBM; de Carli LA; Fantinelli M; Gobbato SS; Bassols GF; Losekann A; Coral GP
    Ann Hepatol; 2018 July - August ,; 17(4):585-591. PubMed ID: 29893699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants.
    Pais R; Lebray P; Rousseau G; Charlotte F; Esselma G; Savier E; Thabut D; Rudler M; Eyraud D; Vezinet C; Siksik JM; Vaillant JC; Hannoun L; Poynard T; Ratziu V
    Clin Gastroenterol Hepatol; 2015 May; 13(5):992-9.e2. PubMed ID: 25459558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 20. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.